PEB - Pacific Edge Ltd

[LoungeLizzard]

Maxtrade suggested folk would choose Cxbladder over a cystoscopy. Unless one has the necessary background to make an informed decision about the reliability of a diagnostic test then I think most, with their lives at stake, would follow the recommendation of someone who is able to make an informed decision. The AUA make informed decisions, and they do not recommend it. The tests are not insured.

I didn't for a moment intend that everyone should think what I do or suggest opinions other than mine wer misinformed. This is a forum, we discuss stocks.

Fair enough. I agree this is a discussion, that encompasses all types of investors with different approaches to investing and different appetites for risk.I didn't see where you were going with "personal choice over science" as if that was a binary thing. Nor with SP movements on the back of misleading announcements. Is that a PEB thing or a general comment?

CXbladder is not designed to replace cystoscopy, rather to augment it. It's not an either or. Where there is, for a example a small amount of urine in the blood (hematuria), the options in the past have been to either ignore it, or go through an invasive procedure that may turn out, in many or most cases, to be completely unnecessary. CXbladder is accurate enough to be able to give an indication of a potential problem ( in which case a cystoscopy may be requested) or to give an all-clear (perhaps with a follow up scan). It's a useful middle path, diagnostic tool. The AUA's own journal of urology said as much in it's performance trial of CXbladder last year:

"For various reasons, many patients who present to primary care with hematuria are not referred for workup. However, the availability of a highly reli- able urine test that enriches the diagnostic yield in the hematuria population improves the proportion of at-risk patients being evaluated, resulting in a higher rate of early UC detection in the patients who are referred for workup. Cxb’s high level of clinical resolution to rule out patients without UC and prioritize others is likely to reduce referral time and enable specialist resources to be focused on patients most likely to have UC, providing a
clinically meaningful benefit and reducing the cost of care."

There re many health providers here in NZ, AUS and the US (including Medicare) that are now using CXBladder. They wouldn't do so if they didn't think it was diagnostically safe. The evidence is already out there, that it is a safe, useful diagnostic tool. The challenge is to get greater uptake. If PEB could get say, Johns Hopkins, on board, wide scale acceptance would follow. And we could all retire as millionaires.

[Maxtrade]

Maxtrade suggested folk would choose Cxbladder over a cystoscopy. Unless one has the necessary background to make an informed decision about the reliability of a diagnostic test then I think most, with their lives at stake, would follow the recommendation of someone who is able to make an informed decision. The AUA make informed decisions, and they do not recommend it. The tests are not insured.

I didn't for a moment intend that everyone should think what I do or suggest opinions other than mine wer misinformed. This is a forum, we discuss stocks.

Cxbladder can be used in conjunction with Cytoscopy. It can help indicate when a Cytoscopy can be recommended to confirm a diagnosis. The advantage is in many cases it can be used to indicate when a Cytoscopy may NOT be needed. ie a Precursor to assist. Non-invasive diagnostic laboratory tests like Cxbladder may be able to accurately rule out bladder cancer without the expense or discomfort of an invasive procedure such as cystoscopy. Multiple trials have demonstrated Cxbladder’s superior performance versus other urine-based tests in accurately ruling out and detecting bladder cancer. There are numerous peer reviewed scientific published studies on Cxbladder urine tests correlated with confirmation of cytoscopy results. The results are very positive. This cancer test has be shown it can reduce the number of invasive procedures required. This is where Cxbladder excels and can establish its place. That is what I meant about stating for those who could opt for a less invasive bladder test versus going straight into a Cytoscopy. Hope that helps clarify.

[psychic]

Yes, agree with that, thanks.

[psychic]

Lounge lizard, yes the misleading announcements comment I made relates to PEB.

[JohnnyTheHorse]

Been some time since I've looked at PEB, but I see the price has near halved in the last 6 months. I take it those 'tens of thousands' of tests still haven't eventuated?

[850man]

Been some time since I've looked at PEB, but I see the price has near halved in the last 6 months. I take it those 'tens of thousands' of tests still haven't eventuated?

No news from PEB since their Sept 1/2 year apart from a Dec notification of a contracted deal with Northern Health in Aust. No news in this case not being good news for investors

[DonkeyKong]

No news from PEB since their Sept 1/2 year apart from a Dec notification of a contracted deal with Northern Health in Aust. No news in this case not being good news for investors

There’s meant to be an investor news letter this month. Crossing my fingers and toes for great news.

[McPussPuss]

Looks like the local instos have taken advantage of the current discount to accumulate.

[DonkeyKong]

Looks like the local instos have taken advantage of the current discount to accumulate.

Where/how do you determine this?

[McPussPuss]

Announcement at market close today, Harbour Asset and Jarden have added 20 million shares between them from my interpretation.